Skip to content

Use of Glidesheath Slender to Reduce Radial Artery Occlusion Following 7 French Transradial Coronary Intervention

Use of Glidesheath Slender to Reduce Radial Artery Occlusion Following 7 French Transradial Coronary Intervention

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04748068
Enrollment
500
Registered
2021-02-10
Start date
2021-02-01
Completion date
2021-05-31
Last updated
2021-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Radial Artery Occlusion

Keywords

Radial artery occlusion, 7-Fr radial sheath, Transradial Coronary Intervention

Brief summary

The objective of this study is to determine the rate of early radial artery occlusion following 7-French(7-Fr) transradial coronary intervention using a new Terumo (Tokyo, Japan) Glidesheath Slender, in comparison with the currently used 7-Fr radial sheath.

Detailed description

Based on previously reported studies the rates of radial artery occlusion using a standard 7-Fr sheath is around 12%, compared to the previous studies of the Glidesheath Slender (see reference in the citations), the rate of radial artery occlusion was reported less than 5%. To prove Slender sheaths are superior to traditional ones, the sample size was estimated according to this, the class I error (α) is set as 0.05 on both sides, and the test efficiency (β) is set as 80%, then at least 248 patients are needed in each group. This study will be a prospective randomized, single-blinded (patient-blinded) study, comparing the rate of radial artery occlusion between the 7-Fr Glidesheath Slender (Terumo, Japan) and the standard 7-Fr radial sheath (cordis, USA) in patients undergoing complex transradial coronary intervention. The study will enroll patients who will undergo elective complex percutaneous coronary intervention (PCI) via 7-Fr transradial approach at Fuwai Hospital National Center for Cardiovascular Diseases. A baseline clinical vascular & ultrasound assessment will be performed prior to the procedure to document patency of the radial artery. Patients will be randomized in 1:1 fashion to either receive the 7-Fr Terumo Glidesheath Slender versus the currently used 7-Fr sheath. The standard angiogram/ PCI will be performed as per usual practice. Following the PCI, clinical vascular assessment as well as an ultrasound will be performed prior to discharge.

Interventions

DEVICE7-Fr Glidesheath Slender

The 7 Fr Glidesheath Slender is a recently developed thin-walled radial sheath. It combines an ID of 2.46 mm, with an OD of 2.79 mm, representing thereby the thinnest 7 Fr sheath currently available on the market

DEVICECordis 7-Fr radial sheath

Avanti+ Catheter Sheath Introducer, Cordis, USA, outer diameter: 3.02 mm

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients undergoing coronary PCI via 7-Fr transradial approach * Informed consent * the patency of radial artery confirmed by ultrasound

Exclusion criteria

* The abnormal of radial artery confirmed by ultrasound * Previous failed radial access. * Known bleeding disorder or hypercoagulable condition * Cardiogenic shock

Design outcomes

Primary

MeasureTime frameDescription
Radial artery occlusion24 hoursEvaluated clinically and by ultrasound

Secondary

MeasureTime frameDescription
Vascular access site complications24 hoursIncludes: bleeding or hematoma, pseudoaneurysm, artery dissection, arteriovenous fistula, compartment syndrome of the forearm
Radial artery spasm24 hoursRadial artery spasm
Procedure success24 hourscompletion of the planned procedure through the initially selected radial access route
The degree of pain at the puncture site24 hoursScored on a scale of 1-10 scoring system

Countries

China

Contacts

Primary ContactHao Wang, MD,PhD
wanghao_fuwai@126.com+86-15701277767

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026